Analysts show differing price targets for CRISPR Therapeutics, with UBS setting a modest $52 target and Citi projecting a bullish $88, driven by expected strong demand for Casgevy, an FDA-approved treatment for sickle cell disease. Despite positive analyst ratings and recent FDA approval, CRISPR's stock trades well below its early-2021 peak, suggesting a potential buying opportunity. Investors also anticipate updates on the CTX310 gene-editing program later in 2026, which could further influence the stock's outlook.
As of Oct 15, 2026 20:22 WIB, CRISPR Therapeutics (CRSP) trades at USD 49.75 on Pluang, slightly down 0.94% for the day. The stock's market cap stands at $4.86 billion with a trading volume of over 1.7 million shares, while all current Pluang orders are buys. The typical hold time for CRSP on Pluang is 77 days, highlighting steady investor interest despite the stock trading below analyst price targets.
